FiercePharma1h
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Sanofi Profit Growth Beats Market View on Early Start of Vaccine Sales
Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...
Sanofi Q3 Profit Rises - Quick Facts
French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...
StamfordAdvocate16h
Sanofi: Q3 Earnings Snapshot
PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...